IPO - bioAffinity Technologies, Inc.

Form Type: S-1

Filing Date: 2025-04-11

Corporate Action: Ipo

Type: New

Accession Number: 000164117225003892

Filing Summary: bioAffinity Technologies, Inc. filed a registration statement on Form S-1 with the SEC on April 11, 2025, to facilitate the resale of 3,013,951 shares of common stock by Selling Stockholders. This includes 2,926,166 shares issuable under common warrants, known as Inducement Warrants, which were part of a private placement transaction conducted on February 25, 2025. Additionally, 87,785 shares are allocated for Advisor Warrants issued to WallachBeth as partial compensation for financial advisory services. The filing aims to satisfy contractual obligations related to these registrations and emphasizes that the company will not receive proceeds from the resale but will benefit from future cash raises upon exercise of the Common Warrants. Common Stock is traded on the Nasdaq under the symbol 'BIAF' and the last reported sale price was $0.63 per share. The document details the proposed use of proceeds, risk factors, and company overview, highlighting the company's focus on developing noninvasive diagnostic tests for early-stage lung cancer and advancing therapeutic discoveries. The effective date for the registration is anticipated soon after it gains SEC approval.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2024-12-04

Corporate Action: Ipo

Type: Update

Accession Number: 000149315224048695

Filing Summary: bioAffinity Technologies, Inc. has requested the U.S. Securities and Exchange Commission to accelerate the effective date of its Registration Statement on Form S-1 (File No. 333-283521) to December 6, 2024, at 5:00 p.m., Eastern Time. This action indicates the company's readiness to proceed with its initial public offering, suggesting a significant step toward raising capital by issuing securities. The Registrant acknowledges its responsibilities under federal securities laws regarding the issuance of these securities. Further, the Registrant has authorized legal representative Leslie Marlow from Blank Rome LLP to modify or withdraw this request as necessary. The communication is signed by Maria Zannes, the Chief Executive Officer of bioAffinity Technologies, Inc.

Document Link: View Document